Health
Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patients – News-Medical.Net
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral…
Reviewed by Emily Henderson, B.Sc.Nov 25 2020
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research
Author: David A. Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in…
-
Noosa News23 hours agoMeasles alert issued across popular south-east attractions
-
General23 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
Noosa News7 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business11 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?